The use of and adherence to CTCAE v3.0 in cancer clinical trial publications

Sheng Zhang1, Qiang Chen2, Qing Wang3

1 Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China
2 Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China
3 Department of Clinical Laboratory, Affiliated Hospital of Qingdao University, China

Correspondence to: Sheng Zhang, email: wozhangsheng@hotmail.com

Keywords: adverse event, CTC, randomized clinical trial

Received: April 04, 2016  Accepted: August 12, 2016  Published: August 24, 2016

ABSTRACT

Background: The Common Terminology Criteria for Adverse Events, Version 3.0 (CTCAE v3.0) was released in 2003, and has been widely used as the predominant set of toxicity criteria for cancer clinical trials and scientific meetings. However, the degree to which the elements of CTCAE v3.0 are followed in oncology publications has not been comprehensively evaluated.

Methods: We reviewed phase III randomized clinical trials evaluating systemic cancer therapies, published between Jan 1, 2012 and December 31, 2013, to identify eligible studies that explicitly mentioned using CTCAE v3.0 as the toxicity criteria. A 10-point score based on adherence to CTCAE v3.0 was used to assess the studies. Multivariate linear regression was used to identify features associated with improved adherence.

Results: In total, 104 publications reporting data on 86,957 patients were included in this analysis. The mean total score for adherence to all four elements of CTCAE v3.0 was 4.03 on a 10-point scale (range, 1 to 9), with 16 publications (15%) having total scores ≤2. Highly heterogeneous and unstandardized adverse event terms were frequently used. In addition, Supra-ordinate terms, terms using ‘Other, specify’, and Grades were often used incorrectly. The multivariate regression model revealed that the absence of a placebo (P=0.003) and a higher total number of AE terms in the table (P<0.001) were independent predictors of a lower total score.

Conclusion: Given the importance of understanding the toxicity of new treatments, better adherence to CTCAE v3.0 should be encouraged to ensure the consistency and comparability of toxicity data across different studies.

INTRODUCTION

Phase III randomized clinical trials (RCTs) are the ideal way to evaluate medical treatments, and their results enable clinicians to work together to recommend appropriate treatments with an understanding of their benefits and risks. As oncology treatments are often highly toxic, more sophisticated methods and standards for reporting the extent and severity of adverse effects are needed in the oncology field than in other fields. Especially considering that most cancer therapies have limited therapeutic indexes, it should be easier to compare cancer studies with one another than non-cancer studies [1–3]. In addition, it is critical to develop more advanced methods of reporting adverse events (AEs) for the purpose of evaluating treatment toxicity in secondary analyses and meta-analyses [4–6].

To facilitate the detection, classification, and documentation of AEs in cancer clinical trials, researchers have created uniform systems of nomenclature, such as the Common Terminology Criteria for Adverse Events (CTCAE)[7], which have been widely used. Though the CTCAE was originally intended for the oncology field, this lexicon is frequently used by physicians making routine care decisions, such as the appropriate dosages of drugs or modes of supportive care. The NCI published...
the third version of the CTCAE (CTCAE v3.0) in 2003 [8], and it became the first complete and standardized system for identifying and grading AEs in multimodality interventions. At present, scientific medical journals and oncology medical meetings primarily use the CTCAE v3.0 to report AE data [7].

The extensive use of CTCAE v3.0 has helped researchers and clinicians to understand the risks related to treatments and compare the toxicities of different anticancer drugs and multimodality treatments [9]. However, the extent to which phase III RCT publications have adhered to CTCAE v3.0 has not been adequately evaluated. In this study, we sought to comprehensively assess the use of CTCAE v3.0 for AE reporting in recent publications of cancer clinical trials by comparing AE terms verbatim between these publications and the CTCAE v3.0 file. In addition, we investigated the trial characteristics associated with higher-quality AE reporting in terms of CTCAE v3.0.

**RESULTS**

**Features of the included RCTs**

Of the studies we initially screened, we included 104 RCTs with data on 86,957 patients, based on their full texts (Figure 1).

Table 1 lists details about the included publications. Lung cancer was the most common type of tumor studied (25%), and the most common type of intervention was chemotherapy plus targeted therapy (38%). The majority of trials (81%) were industry-funded, while approximately 6% were funded by the NCI. Forty-three percent of the trials achieved their expressed primary outcomes. Two journals (Journal of Clinical Oncology and Lancet Oncology) published 77% of the articles (Table 1). Eighty-eight percent of the manuscripts included one AE table, and 9% published two AE tables in the main text.

---

**Figure 1: Flowchart of screening of randomized clinical trials included in this analysis.**
Table 1: Trial Characteristics (N=104)

| Characteristic                                      | No. | %  |
|-----------------------------------------------------|-----|----|
| Sample size                                         |     |    |
| Median                                              | 836 |    |
| Range                                               | 57-4,984 |    |
| Placebo-controlled                                   | 43  | 41 |
| Intervention type                                    |     |    |
| Chemotherapy                                         | 26  | 25 |
| Targeted therapy                                     | 34  | 32 |
| Immunotherapy                                        | 3   | 3  |
| Chemotherapy plus targeted therapy                   | 40  | 38 |
| Chemotherapy plus immunotherapy                      | 1   | 1  |
| Trial met the primary endpoint                       | 45  | 43 |
| Funding source                                       |     |    |
| Industry                                            | 70  | 67 |
| Government                                           | 4   | 4  |
| Industry and government                              | 21  | 20 |
| Not reported                                         | 8   | 7  |
| No funding                                           | 1   | 1  |
| NCI funding                                          | 7   | 6  |
| Cancer type                                          |     |    |
| Breast                                              | 24  | 23 |
| Colorectal                                           | 10  | 10 |
| Lung                                                 | 26  | 25 |
| Gastric or Gastroesophageal                          | 7   | 6  |
| Head and neck                                       | 2   | 2  |
| Melanoma                                             | 3   | 3  |
| Ovarian                                              | 1   | 1  |
| Pancreatic                                           | 2   | 2  |
| Prostate                                             | 9   | 8  |
| Renal                                                | 4   | 4  |
| Other                                                | 16  | 15 |
| Journal                                              |     |    |
| Annals of Oncology                                   | 7   | 7  |
| British Journal of Cancer                            | 2   | 2  |
| The New England Journal of Medicine                  | 6   | 6  |
| The Lancet                                           | 1   | 1  |
| Journal of Clinical Oncology                         | 48  | 46 |
| Lancet Oncology                                      | 32  | 31 |

(Continued)
The remaining 3% only included AE tables in the online appendix.

**Evaluation of the elements of CTCAE v3.0**

As is often the case, the AE reporting was commonly restricted to severe AEs and/or frequent AEs (30% and 64%, respectively). In 89% of the studies, AEs of different severity were pooled (89%)[10, 11]. Thus, the evaluation was based on the available AE data in the tables.

The first required element of CTCAE v3.0 that we evaluated was the use of the standardized AE lexicon. We found widespread use of highly heterogeneous and unstandardized AE terms in the publications we analyzed. For instance, Anemia was frequently used instead of Hemoglobin, Neutropenia was frequently used instead of Neutrophils, and Thrombocytopenia was frequently used instead of Platelets. Only 2% of the 97 studies that included these AEs used them in the proper form, as shown in Table 2.

In CTCAE v3.0, there are 28 CATEGORIES. CATEGORIES are not AEs and should not be reported; however, they were frequently reported in the tables as AEs. For example, Constitutional symptoms, Cardiac general, Hemorrhage, Metabolic and other CATEGORY names were often used. This type of misuse is described as meaningless reporting in the explanatory file of CTCAE v3.0. In addition, some terms reported in the articles were not actually CTCAE v3.0 terms, such as Deterioration in general physical condition, Yellow skin, and many others (Table 2).

In some studies, combinations of different terms (such as nausea-vomiting) were used, even though such terms should be reported separately. Some CTCAE v4.0 terms
Table 2: summary of frequent/representative misuses of CTCAE v3.0

| Section                     | Descriptors in the articles | Correct form or comments                                                                 |
|-----------------------------|-----------------------------|------------------------------------------------------------------------------------------|
| Adverse Events Terms        | Anemia                      | Hemoglobin                                                                               |
|                             | Neutropenia                 | Neutrophils                                                                               |
|                             | Thrombocytopenia            | Platelets                                                                                 |
|                             | Edema                       | Should be Edema-limb or similar                                                           |
|                             | Thromboembolic events       | Not an AE term                                                                            |
|                             | Constitutional symptoms     | Not an AE term                                                                            |
|                             | Vascular                    | Not an AE term                                                                            |
|                             | Cardiac arrhythmia          | Not an AE term                                                                            |
|                             | Palmar-plantar erythrodysesthesia | Not a CTCAE v3.0 term; this is a term in CTCAE v4.0.                                      |
|                             | Fatigue; asthenia           | CTCAE v4.0 term                                                                           |
|                             | Deterioration in general physical condition | Should use Fatigue; they are separate terms in CTCAE v4.0.                                 |
|                             | Decreased appetite          | Not an AE term                                                                            |
|                             | Pyrexia                     | Should use anorexia                                                                        |
|                             | Yellow skin                 | Not an AE term                                                                            |
|                             | Cardiac toxicity            | Not an AE term                                                                            |
|                             | Leukopenia                  | Not an AE term                                                                            |
|                             | Nausea-vomiting             | Leukocytes                                                                                |
|                             | Lacrimation                 | Not an AE term                                                                            |
|                             | Nasopharyngitis             | Not an AE term                                                                            |
|                             | Paresthesia                 | Not an AE term                                                                            |
|                             | Azotemia                    | Not an AE term                                                                            |
|                             | Thyroid disorders           | Not an AE term                                                                            |
|                             | Neutropenic fever           | Not an AE term                                                                            |
|                             | Glossodynia                 | Not an AE term                                                                            |
|                             | Dysphonia                   | Not an AE term                                                                            |
|                             | Abdominal distention        | Not an AE term                                                                            |
|                             | Renal impairment            | Not an AE term                                                                            |
|                             | Menopausal symptoms         | Not an AE term                                                                            |
|                             | Skin exfoliation            | Not an AE term                                                                            |
|                             | Jaundice                    | Not an AE term                                                                            |
|                             | Psychiatric disorders       | Not an AE term                                                                            |
|                             | Epistaxis                   | Not an AE term                                                                            |
|                             | Mucosal inflammation        | Not an AE term                                                                            |
| Supra-ordinate Terms        | Mucositis                   | Should be more specific, for example: mucositis (clinical exam) oral cavity               |
|                             | Mucositis; stomatitis       | They should be the same term rather than different terms.                                  |
|                             | Infection                   | Infection with normal ANC lung                                                             |
|                             | Hemorrhage                  | Should be more specific; for example: Hemorrhage, GI-colon                                |
|                             | Pain                        | Should be more specific; for example: Pain -bone                                           |
|                             | Perforation                 | Should be more specific; for example: Perforation, GU-bladder                             |
|                             | Fistula                     | Should be more specific; for example: fistula, pulmonary-trachea                           |

(Continued)
were also misused as CTCAE v3.0 terms. For example, in CTCAE v3.0, both Fatigue and Asthenia should be reported as Fatigue, while in CTCAE v4.0, Fatigue and Asthenia are different AEs and should be reported separately. This situation also applies to the AE terms of Rash: hand-foot skin reaction in CTCAE v3.0 and Palmar-plantar erythrodysesthesia in CTCAE v4.0. The mixed use of different versions of CTCAE was obvious in some articles, although the authors explicitly mentioned using CTCAE v3.0. For these reasons, the mean score for the first part/element was 0.9. Forty-eight papers had a score of 0 for this section.

The correct use of supra-ordinate terms was the second part of CTCAE v3.0 that we analyzed. The use of these terms was also frequently incorrect. For example, 47 articles used Mucositis as a Supra-ordinate term, but hardly any of them used this term correctly. For this type of term, one word should be selected from the words listed after the Supra-ordinate term to make it more specific (e.g., Mucositis (clinical exam)- oral cavity). A variety of other Supra-ordinate terms were frequently misused, including Hemorrhage, Pain, Perforation, Fistula, and others, as shown in Table 2. The mean score for this section was 0.68. Forty-eight papers had a score of 0 for this section.

The correct use of supra-ordinate terms was the second part of CTCAE v3.0 that we analyzed. The use of these terms was also frequently incorrect. For example, 47 articles used Mucositis as a Supra-ordinate term, but hardly any of them used this term correctly. For this type of term, one word should be selected from the words listed after the Supra-ordinate term to make it more specific (e.g., Mucositis (clinical exam)- oral cavity). A variety of other Supra-ordinate terms were frequently misused, including Hemorrhage, Pain, Perforation, Fistula, and others, as shown in Table 2. The mean score for this section was 0.68.

The correct use of supra-ordinate terms was the second part of CTCAE v3.0 that we analyzed. The use of these terms was also frequently incorrect. For example, 47 articles used Mucositis as a Supra-ordinate term, but hardly any of them used this term correctly. For this type of term, one word should be selected from the words listed after the Supra-ordinate term to make it more specific (e.g., Mucositis (clinical exam)- oral cavity). A variety of other Supra-ordinate terms were frequently misused, including Hemorrhage, Pain, Perforation, Fistula, and others, as shown in Table 2. The mean score for this section was 0.68.

In the rare event that a suitable CTCAE v3.0 term cannot be found, the ‘Other, specify’ mechanism can be used. The investigator must first identify the most appropriate CTCAE v3.0 CATEGORY to classify the event. Within each CATEGORY, there is a CTCAE v3.0 term ‘Other’ (e.g., ‘Cardiac Arrhythmia - Other’). After selecting ‘Other’, the submitter must describe or ‘specify’ the adverse event. This was another requirement that we evaluated. Only four studies used this type of term, and none of them used it correctly. Generally, no further description was given after the term ‘Other’. The mean score for this section was 0.96.

The severity of an AE is indicated with a Grade. In some publications, the grading was also an issue. For example, a substantial number of papers assigned grades of 1 or 2 for Febrile neutropenia, when 3 is the minimum grade for this term in CTCAE v3.0. Likewise, in some reports, Alopecia was given a grade of 3 or more, while the maximum grade for this term is 2 in CTCAE v3.0. A summary of this kind of misuse is given in Table 2. The mean score for this section was 1.48.

Rating of the total score according to CTCAE v3.0 Adherence

The mean total score for all four elements was 4.03 on a 10-point scale, with 16 publications (15%) having total scores ≤2. Only three trials received a score of 9, and no trial had a score of 10.

In the multivariate regression model, we found that placebo group inclusion (P=0.003), the funding source (P=0.012), the publication journal (P=0.02), and the total number of AE terms in the table (P<0.001) independently predicted the total score.

DISCUSSION

In the design of medical interventions, it is critical to strike a balance between efficacy and toxicity, as many anticancer drugs may be so toxic that they become less...
beneficial [9]. Properly reporting AEs is an important part of performing and reviewing RCTs. The CTCAE was created because investigators saw the need for a concise and standardized dictionary of AEs and their severity. CTCAE v3.0 is now the standard lexicon used to document AEs in all types of cancer clinical trials [7]. As far as we know, our study is the first to investigate a large number of oncology RCT publications for their conformance to CTCAE v3.0 when they explicitly mentioned using it to evaluate toxicity.

We created a scoring system for adherence to CTCAE v3.0 with the consensus of our group. This rating system was imperfect, since articles that reported more AE terms/grades had higher chances of misusing the terms and thus receiving lower scores. Conversely, publications that used fewer AE terms/grades could have had higher scores, although the former may have had higher-quality procedures for collecting, analyzing and reporting toxicity data [12]. However, the sole purpose of this study was to assess adherence to CTCAE v3.0, not to investigate other aspects of toxicity quality. Thus, higher scores only represented the correctness of adherence to CTCAE v3.0.

Most of the articles we included were deficient or incorrect for the four elements of CTCAE v3.0. The mean score for AE terms was only 0.9 on a scale of 0 to 5, and a large number of reported AEs did not match the standardized lexicon in CTCAE v3.0. This also applied to the use of Supra-ordinate terms and ‘Other, specify’. Moreover, some terms from CTCAE v4.0 were misattributed to CTCAE v3.0, and grades were often misused. Considering that a large number of studies only published the “pooled,” “selected,” or “worst” AEs (which could not be analyzed in detail for the four elements of interest) and that we only evaluated the AEs in the tables, the true scores and adherence to CTCAE v3.0 may have been even lower.

There are several potential reasons for the poor adherence to CTCAE v3.0 (mean total score of 4.03 on a scale of 0 to 10) revealed in our study. A significant factor may be that authors are unaware of the explanatory file for CTCAE v3.0. Indeed, while CTCAE v3.0 has been widely used as the predominant source of AE vocabulary, some important content can only be found in the accompanying explanatory file on the NCI website, so lack of familiarity with this document may prevent authors and editors from correctly using CTCAE v3.0. Another reason might be conceptual differences in assessing drug toxicity from a clinical perspective and assessing adverse events in a clinical trial. The main goal of clinical investigators writing a manuscript might be to report only the adverse events that they consider meaningful for their readers (often clinicians). To achieve this goal, investigators might want to summarize the long lists of AEs provided by the NCI CTCAE.

In our study, 22% of the studies that used the term ‘Febrile neutropenia’ assigned grades of 1 or 2, although the minimum grade is 3 according to CTCAE v3.0. This kind of misgrading also applied to a number of other objective AEs, as shown in Table 3. Thus, we have further extended these findings, as we specifically evaluated the quality and correctness of grading according to the standards of CTCAE v3.0.

It is noteworthy that most of the variables we evaluated in our adjusted analyses, including journal impact factor, were not related to adherence to CTCAE v3.0. These results suggest that poor adherence is a universal phenomenon. In NCI-sponsored trials, one of the minimum reporting requirements is adherence to CTCAE, and this process is partly audited [7]. We anticipated that the NCI-sponsored trials in this analysis would have higher total scores, but in fact, these trials were similar to other trials in their poor adherence to CTCAE v3.0. This observation is difficult to explain. Since there were only seven studies sponsored by the NCI in this analysis, this finding may need to be confirmed in future studies.

Several factors were associated with higher total scores in this study, including the presence of a placebo group. It may be that the higher total scores among placebo-controlled RCTs in this study were the result of higher-quality procedures for collecting toxicity data, and/or the expectation that the oncology community would more closely scrutinize safety data coming from placebo-controlled RCTs [10, 13].

This study had several potential limitations. We only analyzed publications from the past two years from randomized phase III trials of solid tumor treatments, although phase II trials, hematologic malignancy trials and multimodality treatment trials (for instance, studies of radiation therapy) should also be required to adhere to CTCAE v3.0. However, considering the importance of phase III RCTs in clinical decision-making, our results indicate that there is cause for concern about adherence to the specified toxicity criteria. Moreover, our analysis was limited to the AE tables in the publications, so it is possible that the descriptions of AEs in the text were also problematic with respect to our criteria. CTCAE v4.0 was published in 2009 and has gradually been accepted and used in clinical trials. However, the current literature is still primarily composed of studies using version 3.0. Furthermore, the essential components of CTCAE were not changed between versions 3.0 and 4.0, so the problems identified here may also carry over to version 4.0 and future versions.

There are ways that adherence could be improved in the future. Since health providers seemed to be unfamiliar with the explanatory file for CTCAE v3.0, we suggest that this explanatory file be incorporated into the main file of CTCAE v3.0. In addition, the changes in some AE lexicons between CTCAE v3.0 and 4.0 (for example, from using the same AE term for Fatigue and Asthenia in version 3.0 to using different AEs for these two words in version 4.0) may be confusing, particularly in international or cooperative clinical trials.
Table 3: results of the regression analysis of factors predicting the total score (scale, 0 to 10)

| Study characteristic | Total score | Linear regression | Univariate analysis | Multivariate analysis |
|----------------------|-------------|-------------------|---------------------|----------------------|
|                      |             |                   |                     |                      |
|                      | Mean | SE  | Estimate* | SE  | P       | Estimate* | SE  | P       |
| Sample               | -    | -   | 1.886E-04 | 1.86E-04 | 0.313   | 0.0001534 | 0.000186 | 0.410761 |
| Placebo-controlled   |      |      |           |         |         |           |       |         |
| No                   | 3.69 | 1.66 | Reference | 0.024 | Reference | 0.9593004 | 0.314109 |
| Yes                  | 4.51 | 2.00 | 0.823    | 0.360 | 0.9593004 | 0.314109 |
| Intervention type    |      |      |           |         |         |           |       |         |
| Chemotherapy         | 4.31 | 1.692 | Reference | 0.094 | Reference | 0.782623 |
| Targeted therapy     | 4.26 | 2.122 | -0.043   | 0.4714 | 0.4688728 | 0.543153 |
| Immunotherapy        | 6    | 1    | 1.692    | 1.1033 | 2.0597306 | 0.950609 |
| Chemotherapy plus targeted therapy | 3.53 | 1.617 | -0.783   | 0.4558 | 0.2348105 | 0.462439 |
| Chemotherapy plus immunotherapy | 3 | - | -1.308 | 1.8439 | 1.4034875 | 1.537668 |
| Year of publication  |      |      |           |         |         |           |       |         |
| 2012                 | 3.78 | 1.62 | Reference | 0.344 | Reference | 0.907394 |
| 2013                 | 4.26 | 1.987 | 0.483    | 0.3777 | 0.0294972 | 0.339883 |
| Funding source       |      |      |           |         |         |           |       |         |
| Industry             | 3.73 | 1.685 | Reference | 0.053 | Reference | 0.012035 |
| Government           | 3.5  | 2.082 | -0.229   | 0.9238 | 0.2567488 | 0.938224 |
| Industry and government | 5.05 | 1.91 | 1.319    | 0.4471 | 1.1287793 | 0.431095 |
| Not reported         | 4.38 | 2.326 | 0.646    | 0.6706 | 0.3026393 | 0.611195 |
| No funding           | 3    | -    | -0.729   | 1.8097 | -1.002272 | 1.475745 |
| NCI funding          |      |      |           |         |         |           |       |         |
| No                   | 4.04 | 1.806 | Reference | 0.808 | Reference | 0.986299 |
| Yes                  | 3.88 | 2.416 | -0.167   | 0.6824 | -0.009576 | 0.556064 |
| Cancer type          |      |      |           |         |         |           |       |         |
| Breast               | 3.91 | 1.857 | Reference | 0.134 | Reference | 0.281474 |
| Colorectal           | 4.12 | 1.862 | 0.092    | 0.5205 | -0.365837 | 0.4654 |
| Lung                 | 3.9  | 1.595 | -0.070   | 0.6854 | 0.3708219 | 0.607385 |
| Gastric or Gastroesophageal | 3.43 | 1.902 | -0.542   | 0.7800 | -0.675343 | 0.647276 |
| Head and neck        | 5    | 1.414 | 1.030    | 1.3279 | 2.6800736 | 1.315862 |
| Melanoma             | 6.67 | 2.082 | 2.696    | 1.1065 | 1.1717029 | 0.94511 |
| Ovarian              | 4    | -    | 0.030    | 1.8386 | -2.447859 | 1.643422 |
| Pancreatic           | 5.5  | 3.536 | 1.530    | 1.3279 | 1.4821869 | 1.0373 |
| Prostate             | 3.56 | 1.944 | -0.415   | 0.7111 | -0.424911 | 0.627381 |

(Continued)
| Study characteristic | Linear regression |  |
|----------------------|-------------------|---|
|                      | Total score       | Univariate analysis | Multivariate analysis |
|                      | Mean  | SE   | Estimate*  | SE   | P     | Estimate*  | SE   | P     |
| Renal                | 2     | 0.816 | -1.970     | 0.9772 |       | -0.227263 | 0.911072 |
| Other                | 4.35  | 1.539 | 0.383      | 0.5801 |       | 0.5433376 | 0.587407 |
| Journal              |        |      |            |       |       |            |       |       |
| Annals of Oncology   | 2.33  | 1.966 | Reference  | 0.065 |       | Reference  | 0.019737 |
| British Journal of Cancer | 3.56 | 1.74  | 1.229      | 0.7950 |       | -0.552375 | 0.34583 |
| The New England Journal of Medicine | 5     | -     | 2.667      | 1.9303 |       | -1.04082  | 1.683718 |
| The Lancet           | 3.29  | 0.488 | 0.952      | 0.9943 |       | -1.312478 | 0.812905 |
| Journal of Clinical Oncology | 4.5   | 0.707 | 2.167      | 1.4592 |       | 0.0943333 | 1.180544 |
| Lancet Oncology      | 4.5   | 1.868 | 2.167      | 0.7738 |       | 0.9188062 | 0.685869 |
| European Journal of Cancer | 4.67 | 3.215 | 2.333      | 1.2637 |       | 0.4202688 | 0.882833 |
| Other                | 4.8   | 1.304 | 2.467      | 1.0822 |       | -0.619529 | 0.924878 |
| Cancer stage         |        |      |            |       |       |            |       |       |
| Adjuvant and/or neoadjuvant | 4.6 | 2.23  | Reference  | 0.197 |       | Reference  | 0.099655 |
| Metastatic           | 3.93  | 1.77  | -0.67      | 0.5135 |       | -0.862935 | 0.518569 |
| Impact factors of journals | - | - | -0.04 | 0.0184 | 0.029 | 0.0093691 | 0.020649 | 0.651137 |
| Region in which RCT was led |       |      |            |       |       |            |       |       |
| International        | 3.88  | 1.916 | Reference  | 0.008 |       | Reference  | 0.151213 |
| North America        | 5.44  | 2.186 | 1.56       | 0.637622 |       | 1.7777755 | 0.667148 |
| Europe               | 3.47  | 1.432 | -0.42      | 0.404917 |       | -0.139318 | 0.385868 |
| Others               | 4.92  | 1.498 | 1.04       | 0.547652 |       | 0.9635998 | 0.500368 |
| Trial met primary endpoint |       |      |            |       |       |            |       |       |
| No                   | 4.24  | 1.832 | Reference  | 0.189 |       | Reference  | 0.566976 |
| Yes                  | 3.76  | 1.848 | -0.48      | 0.363988 |       | 0.2028404 | 0.352964 |
| No. of AE terms in the table | - | - | -0.07 | 0.017528 | 0 | 0.4782561 | 0.15652 | 0.002973 |
| Total no. of terms in the table | - | - | -0.07 | 0.016521 | 0 | -0.528135 | 0.148988 | 0.000632 |

Abbreviations: RCT, randomized controlled trial.* Scale range of 0 to 10. The estimates shown indicate the incremental benefit observed compared with the reference level. Any positive value indicates the benefit compared with the reference, whereas any negative value indicates a detriment compared with the reference.
In summary, we have demonstrated that there is significant heterogeneity and incorrectness in the use of CTCAE v3.0 in oncology clinical trial publications. Stricter adherence to these toxicity criteria should be followed.

MATERIALS AND METHODS

Trial selection

We used “randomized” and “cancer” as keywords to search MEDLINE via PubMed in April, 2014. The filters were “clinical trial phase III”; “English”; “humans”; “1/1/2012 - 12/31/2013” and “Adult: 18+ years”. Publications were limited to trials exploring pharmacologic interventions in patients with solid tumors. We excluded observational studies, case reports, editorials, letters, meta-analyses, phase 1 and 2 studies, studies exploring devices or behavioral interventions, hematological studies, supportive care studies, studies with journal impact factors less than 3, secondary reports on previously published trials, and studies in which CTCAE v3.0 was not explicitly stated as the set of toxicity criteria.

Development of a quantitative scoring system for CTCAE v3.0

CTCAE v3.0 was released in 2003 and was followed with a minor revision. An explanatory PowerPoint file entitled ‘Responsible Adverse Event Reporting: Finding Appropriate AE Terms.’ also accompanied the release of CTCAE v3.0 (http://ctep.cancer.gov/protocolDevelopment/electronic_applications/cte.htm). Therefore, for the purpose of our analysis, we assembled a multidisciplinary panel of nine clinical oncology health care providers, including medical oncologists, clinical research nurses, and two oncology pharmacists, to review the CTCAE v3.0 file, minor revision file and explanatory file. As a result of this process, four key elements were identified and incorporated into the data collection form, as outlined in Table 4.

The standardized AE lexicon was required and was assigned five points in our scoring system, as it comprises the major part of CTCAE v3.0.

A supra-ordinate term is a grouping term. It is followed by the word ‘Select’ and is accompanied by specific AEs that are all related. The correct use of supra-ordinate terms was regarded as the second requirement, and was assigned two points in our scoring system.

Grade refers to the severity of an AE. The correct use of Grades was evaluated as a third component of CTCAE v3.0, and was assigned two points.

The AE term ‘Other, specify’ can be used when an appropriate AE term cannot be found. To use this term correctly, the investigator should identify the appropriate category in CTCAE v3.0, select the word ‘Other’ within that category, and provide a short description. Thus, the correct use of the term ‘Other, specify’ was the fourth scored component of CTCAE v3.0, and was assigned one point because this type of AE term is used infrequently.

To determine the correctness of the included manuscripts, we recorded each AE term or grade mentioned by the authors, and searched for them verbatim using the ‘search’ tool in the pdf file of CTCAE v3.0 and the revision file, as instructed by the explanatory file. One point was deducted for each misused AE term/Grade according to these files. The minimum score for each section was 0. The maximum total score according to these rating criteria (10 points) was automatically given to each paper before the rating. The score for each element was rated, and the total score was calculated as the sum of the scores of each element. When a term could be categorized as an AE term as well as a Supra-ordinate term, such as ‘infection’, it was analyzed as a Supra-ordinate term in this study.

AE terms/grades may be used in the text, summarized AE tables or supplemental documents of a manuscript. Generally, the most significant AE terms/grades are summarized in table form, so we decided to evaluate the contents of AE tables for this analysis. Occasionally, AE tables were absent from the main text but were shown in the online appendix. In these cases, the AE tables from the online documents were analyzed.

Data extraction

Eligible publications were evaluated for the four elements of CTCAE v3.0 on which we based our scoring system. Additional data extracted from each article included the study sample size, intervention type, use of a placebo control, funding source, cancer type, cancer stage, publication year, journal name, impact factor, and whether the primary endpoint was met. The numbers of AE terms, supra-ordinate terms, terms using ‘Other’ and total terms in the AE tables were also recorded for each article.

The scoring system was pilot-tested on 15 randomly selected trials by two investigators (S.Z. and Q.C.) who were blinded to each other’s results. Any discrepancy was identified and resolved successfully by the consensus of all the authors of this study. Cronbach’s alpha was 0.7. Based on this finding, a standardized data extraction form was used by these two authors to capture the remaining data in this study. No protocol for this study exists.

Statistical analysis

The primary objective was to describe the correct use of standardized AE terms/Grades in randomized oncology clinical trial publications in the context of CTCAE v3.0. The secondary objective was to assess trial characteristics associated with the total score of each article.
Univariate and multivariate linear regression analyses were used to identify factors associated with higher total scores. The following trial characteristics were investigated: tumor site, funding source, year of publication, journal impact factor, geographic region, type of investigational therapy, cancer stage, sample size, primary outcome, the number of AE terms and the total number of terms. Statistical analyses were performed in SAS version 9.2 (SAS, Cary, NC, USA), with two-sided P values.

CONFLICTS OF INTEREST

The authors declare no conflicts of interest.

REFERENCES

1. Trotti A, Bentzen SM. The need for adverse effects reporting standards in oncology clinical trials. J Clin Oncol. 2004; 22: 19-22. doi: 10.1200/jco.2004.10.911.
2. Kuderer NM, Wolff AC. Enhancing therapeutic decision making when options abound: toxicities matter. J Clin Oncol. 2014; 32: 1990-3. doi: 10.1200/jco.2014.55.1903.
3. Trotti A, Pajak TF, Gwede CK, Paulus R, Cooper J, Forastiere A, Ridge JA, Watkins-Bruner D, Garden AS, Ang KK, Curran W. TAME: development of a new method for summarising adverse events of cancer treatment by the Radiation Therapy Oncology Group. Lancet Oncol. 2007; 8: 613-24. doi: 10.1016/s1470-2045(07)01444-4.
4. Seng S, Liu Z, Chiu SK, Proverbs-Singh T, Sonpavde G, Choueiri TK, Tsao CK, Yu M, Garden AS, Ang KK, Curran W. Risk of venous thromboembolism in patients with cancer treated with cisplatin: a systematic review and meta-analysis. J Clin Oncol. 2012; 30: 4416-26. doi: 10.1200/jco.2012.42.4358.
5. Proverbs-Singh T, Chiu SK, Liu Z, Seng S, Sonpavde G, Choueiri TK, Tsao CK, Yu M, Hahn NM, Oh WK, Galsky MD. Arterial thromboembolism in cancer patients treated with cisplatin: a systematic review and meta-analysis. J Natl Cancer Inst. 2012; 104: 1837-40. doi: 10.1093/jnci/djs435.
6. Ranpura V, Hapani S, Wu S. Treatment-related mortality with bevacizumab in cancer patients: a meta-analysis. JAMA. 2011; 305: 487-94. doi: 10.1001/jama.2011.51.
7. Trotti A, Colevas AD, Setser A, Basch E. Patient-reported outcomes and the evolution of adverse event reporting in oncology. J Clin Oncol. 2007; 25: 5121-7. doi: 10.1200/jco.2007.12.4784.
8. Trotti A, Colevas AD, Setser A, Rusch V, Jacques D, Budach V, Langer C, Murphy B, Coleman CN, Rubin P. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol. 2003; 13: 176-81. doi: 10.1016/s1053-4296(03)00031-6.
9. Niraula S, Seruga B, Ocana A, Shao T, Goldstein R, Tannock IF, Amir E. The price we pay for progress: a meta-analysis of harms of newly approved anticancer drugs. J Clin Oncol. 2012; 30: 3012-9. doi: 10.1200/jco.2011.40.3824.
10. Peron J, Maillet D, Gan HK, Chen EX, You B. Adherence to CONSORT adverse event reporting guidelines in randomized clinical trials evaluating systemic cancer therapy: a systematic review. J Clin Oncol. 2013; 31: 3957-63. doi: 10.1200/jco.2013.49.3981.
11. Sivendran S, Latif A, McBride RB, Stensland KD, Wisnivesky J, Haines L, Oh WK, Galsky MD. Adverse
event reporting in cancer clinical trial publications. J Clin Oncol. 2014; 32: 83-9. doi: 10.1200/jco.2013.52.2219.

12. Dorr DA, Burdon R, West DP, Lagman J, Georgopoulos C, Belknap SM, McKoy JM, Djulbegovic B, Edwards BJ, Weitzman SA, Boyle S, Tallman MS, Talpaz M, et al. Quality of reporting of serious adverse drug events to an institutional review board: a case study with the novel cancer agent, imatinib mesylate. Clin Cancer Res. 2009; 15: 3850-5. doi: 10.1158/1078-0432.ccr-08-1811.

13. Peron J, Pond GR, Gan HK, Chen EX, Almufti R, Maillet D, You B. Quality of reporting of modern randomized controlled trials in medical oncology: a systematic review. J Natl Cancer Inst. 2012; 104: 982-9. doi: 10.1093/jnci/djs259.